相似文献
1
Chemotherapy-induced peripheral neuropathy: A current review.
Ann Neurol. 2017 Jun;81(6):772-781. doi: 10.1002/ana.24951. Epub 2017 Jun 5.
2
Chemotherapy-induced peripheral neurotoxicity.
Curr Opin Neurol. 2015 Oct;28(5):500-7. doi: 10.1097/WCO.0000000000000234.
3
Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study.
Support Care Cancer. 2019 May;27(5):1765-1774. doi: 10.1007/s00520-018-4424-6. Epub 2018 Aug 27.
4
Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge.
Cancer Treat Rev. 2016 Nov;50:118-128. doi: 10.1016/j.ctrv.2016.09.005. Epub 2016 Sep 10.
5
Individually tailored whole-body vibration training to reduce symptoms of chemotherapy-induced peripheral neuropathy: study protocol of a randomised controlled trial-VANISH.
BMJ Open. 2019 Apr 24;9(4):e024467. doi: 10.1136/bmjopen-2018-024467.
6
A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Support Care Cancer. 2017 Jan;25(1):195-204. doi: 10.1007/s00520-016-3404-y. Epub 2016 Sep 9.
7
Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
Brain Behav. 2019 Jun;9(6):e01312. doi: 10.1002/brb3.1312. Epub 2019 May 7.
8
Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy.
BMC Cancer. 2018 Dec 4;18(1):1203. doi: 10.1186/s12885-018-5093-z.
9
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update.
J Clin Oncol. 2020 Oct 1;38(28):3325-3348. doi: 10.1200/JCO.20.01399. Epub 2020 Jul 14.
10
Identifying trajectories and predictors of chemotherapy-induced peripheral neuropathy symptoms, physical functioning, and falls across treatment and recovery in adults treated with neurotoxic chemotherapy: the PATTERN observational study protocol (NCT05790538).
BMC Cancer. 2023 Nov 10;23(1):1087. doi: 10.1186/s12885-023-11546-2.
引用本文的文献
1
Impact of Population Pharmacogenomics on Cisplatin-Induced Neurotoxicities in Testicular Cancer Survivors.
Cancer Med. 2025 Sep;14(17):e71218. doi: 10.1002/cam4.71218.
2
Suppression of Paclitaxel-Induced Neuropathy and Ovarian Tumor Growth by Mn Porphyrin, MnTnBuOE-2-PyP (BMX-001).
Oxid Med Cell Longev. 2025 Aug 24;2025:6333148. doi: 10.1155/omcl/6333148. eCollection 2025.
3
[Not Available].
Can Oncol Nurs J. 2025 Jan 1;35(1):89-102. doi: 10.5737/2368807635189. eCollection 2025 Winter.
4
Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain.
Pharmaceuticals (Basel). 2025 Aug 5;18(8):1159. doi: 10.3390/ph18081159.
5
Comparative Effects of THC and CBD on Chemotherapy-Induced Peripheral Neuropathy: Insights from a Large Real-World Self-Reported Dataset.
Biomedicines. 2025 Aug 6;13(8):1921. doi: 10.3390/biomedicines13081921.
6
Food groups and micronutrients associated with chemotherapy-induced peripheral neuropathy in survivors of cancer post-neurotoxic treatment.
Support Care Cancer. 2025 Aug 23;33(9):806. doi: 10.1007/s00520-025-09827-6.
7
Percutaneous Peripheral Nerve Stimulation in Chemotherapy-Induced Neuropathy: A Case Report.
Reports (MDPI). 2025 Aug 1;8(3):133. doi: 10.3390/reports8030133.
8
Ribosome profiling reveals that post-transcriptional control of Nalf1 by heterogeneous nuclear ribonucleoprotein L is required for paclitaxel-induced neuropathic pain.
Pain. 2025 Apr 2;166(9):2091-2102. doi: 10.1097/j.pain.0000000000003577.
9
The efficacy of acupuncture in the treatment of chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis.
J Cancer Surviv. 2025 Aug 19. doi: 10.1007/s11764-025-01869-3.
10
Dietary Carvacrol Attenuates Cyclophosphamide-Induced Neurotoxicity: Implications for Food-Derived Neuroprotection and Molecular Mechanisms.
Food Sci Nutr. 2025 Aug 7;13(8):e70734. doi: 10.1002/fsn3.70734. eCollection 2025 Aug.
本文引用的文献
1
Neuropathies associated with lymphoma.
Neurooncol Pract. 2015 Dec;2(4):167-178. doi: 10.1093/nop/npv025. Epub 2015 Aug 1.
2
Vasculitic neuropathy induced by pembrolizumab.
Ann Oncol. 2017 Feb 1;28(2):433-434. doi: 10.1093/annonc/mdw613.
3
Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice.
Brain. 2016 Dec;139(Pt 12):3092-3108. doi: 10.1093/brain/aww251. Epub 2016 Oct 25.
4
Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy.
N Engl J Med. 2016 Jul 21;375(3):296-7. doi: 10.1056/NEJMc1515584.
5
Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.
J Clin Oncol. 2016 Aug 10;34(23):2712-20. doi: 10.1200/JCO.2016.66.8822. Epub 2016 Jun 27.
6
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.
Eur J Cancer. 2016 Jun;60:210-25. doi: 10.1016/j.ejca.2016.02.024. Epub 2016 Apr 13.
7
Scrambler Therapy for the management of chronic pain.
Support Care Cancer. 2016 Jun;24(6):2807-14. doi: 10.1007/s00520-016-3177-3. Epub 2016 Apr 4.
8
Paclitaxel-induced epithelial damage and ectopic MMP-13 expression promotes neurotoxicity in zebrafish.
Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):E2189-98. doi: 10.1073/pnas.1525096113. Epub 2016 Mar 28.
9
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.
Breast Cancer Res. 2016 Mar 15;18(1):34. doi: 10.1186/s13058-016-0691-7.
10
Pluripotent stem cells in disease modelling and drug discovery.
Nat Rev Mol Cell Biol. 2016 Mar;17(3):170-82. doi: 10.1038/nrm.2015.27. Epub 2016 Jan 28.
Zotero 插件